Table 4 Antimicrobial treatment in relation to de-escalation policy
Antimicrobial combination | Non-de-escalation | De-escalation | p |
|---|---|---|---|
2006-2009 study period (n,%) | |||
β-lactamase inhibitors | 0 (0) | 15 (28.3) | |
2nd generation cephalosporins | 0 (0) | 16 (30.2) | |
3rd generation cephalosporins | 6 (14.6) | 2 (3.8) | |
Piperacillin/tazobactam | 27 (65.8) | 3 (5.6) | <0.0001 |
Carbapanem | 3 (.3) | 0 (0) | |
Carbapanem + glycopeptide | 5 (12.2) | 0 (0) | |
Ciprofloxacin | 0 (0) | 17 (32.1) | |
2010-2013 study period (n,%) | |||
β-lactamase inhibitors | 0 (0) | 8 (22.2) | |
2nd generation cephalosporins | 0 (0) | 15 (41.7) | |
3rd generation cephalosporins | 7 (7.5) | 5 (13.9) | |
Piperacillin/tazobactam | 59 (63.4) | 2 (5.5) | <0.0001 |
Piperacillin/tazobactam + glycopeptide | 9 (9.7) | 0 (0) | |
Carbapanem | 10 (10.8) | 0 (0) | |
Carbapanem + glycopeptide | 8 (8.6) | 0 (0) | |
Ciprofloxacin | 0 (0) | 6 (16.7) | |